The Jury of the 8th edition of The 50 Most Creative in Business ranking has decided – Łukasz Bzdzion, Bioceltix CEO, took the second place. The founder of Bioceltix noted that already every fifth dog experiences suffering associated with degenerative joint changes. Our company combines imagination with scientific knowledge, due to which we create a safe and effective alternative for synthetic drugs. On behalf of our CEO, we would like to thank you for this special distinction.
On behalf of our CEO, we would like to thank you for this special distinction.
Puls Biznesu about our plans: Bioceltix announces that it will soon debut on NewConnect – the company has recently completed the pre-IPO round. So far, the company has obtained a total of approx. PLN 20 million in financing for the development of a still innovative method of treating pets ...
ArticleForbes about Polish start-ups in the coronavirus crisis: “The year 2020 was a big challenge for companies, individual sectors of the economy and probably all of us. In the coming weeks and months of 2021 it will be similar. The condition of start-ups is no exception here. it is easier and ...
ArticleAccording to the „Investors’ Zone”, an interesting year is being prepared on the stock exchange: “This year, an exceptionally large group of companies is choosing NewConnect. As many as 63 companies declared their willingness to enter the alternative market, and several more in the ...
ArticleGazeta Wrocławska wrote about us: “Bioceltix is working on innovative biological medicines used in the treatment of common autoimmune and inflammatory diseases in companion animals. The company from Wrocław has something to fight for. This is indicated by the numbers on the global drug ...
ArticleWe create at Bioceltix veterinary biological medicines, and in 2020 we announced plans for a stock exchange debut and we obtained a permit from the Main Pharmaceutical Inspector to manufacture veterinary biological drugs. Despite the pandemic, we continue our projects without downtime. You can ...
ArticleAs the first company in Europe, Bioceltix intends to authorize a veterinary biopharmaceutical based on stem cells. Łukasz Bzdzion, the CEO of the ...
Read fullWe was on Impact’18, congress that brings leaders at the forefront of innovation from many sectors together to explore the opportunities ...
Read fullCEO of Bioceltix, Łukasz Bzdzion, during the WallStreet conference in Karpacz talked about the AlloMSCs technology, biopharmaceuticals based on ...
Read full
